RecruitingPhase 4NCT06535945

Influence of Human Albumin Supplementation on Kidney Dysfunction After Liver Transplantation


Sponsor

Rennes University Hospital

Enrollment

400 participants

Start Date

Mar 26, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

To verify whether albumin administration to achieve serum concentration above 30g/L (treated group) and its maintenance within plasmatic physiologic range (above 30 g/L) for five days diminishes rate of AKI at Day 7 after liver transplantation as compared to restrained albumin administration (when serum concentration is at 20 g/L or below (control)).


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Male and female subjects equal or above 18 yrs old.
  • Recipients of primary liver allografts from a deceased donor (including after cardiac death) and as a single organ (liver only).
  • Capability of understanding the purpose and risks of the study.
  • Written informed consent

Exclusion Criteria5

  • Fulminant hepatitis
  • Kidney injury at baseline (Estimated Glomerular Filtration Rate < 50 ml/min in Modification of diet in renal disease-6) including hepatorenal syndrome
  • Use of an induction agent Basiliximab at liver transplantation
  • Protected person (adults legally protected, under judicial protection, guardianship, or supervision), person deprived of their liberty
  • At the time of randomisation, participation to another interventional study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAlbumin administration

when albumin serum concentration is at 30 g/L or below


Locations(8)

08_CHRU de Tours Hôpital Trousseau

Chambray-lès-Tours, France

03_APHP Hôpital Beaujon

Clichy, France

04_CHU de Lille Hôpital Huriez

Lille, France

05_HCL Hôpital de la Croix Rousse

Lyon, France

06_CHU de Montpellier Hôpital St Eloi

Montpellier, France

02_CHU de Bordeaux - Hôpital Haut Leveque

Pessac, France

01_CHU de Rennes Hôpital Pontchaillou

Rennes, France

09_APHP Hôpital Paul Brousse

Villejuif, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06535945


Related Trials